Traders assign a 93% probability against a new COVID variant of concern emerging before 2027 because no SARS-CoV-2 lineage currently meets WHO or ECDC criteria for that designation, even after extensive genomic tracking of Omicron subvariants. Recent surveillance through mid-2026 shows strains like BA.3.2 (nicknamed Cicada), NB.1.8.1, and XFG circulating at notable levels in wastewater and sequences yet producing no meaningful rise in severity, transmissibility, or immune escape that would trigger reclassification. Dominant lineages such as XFG.1.1 continue evolving modestly without crossing public-health thresholds, while overall case incidence and emergency visits remain very low. Updated 2026-2027 vaccine formulations target these same lineages, underscoring the view that the virus has entered a phase of incremental drift rather than disruptive shifts likely to prompt a formal variant-of-concern label in the remaining months of the year.